Cargando…

Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial

BACKGROUND AND AIMS: Ulcerative colitis [UC] impacts patients’ health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint (‘Comprehensive Disease Control’ [CDC]) in individuals receiving filgotinib [an oral JAK1 preferential inhibitor] in the SELECT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreiber, Stefan, Feagan, Brian G, Peyrin-Biroulet, Laurent, Vermeire, Séverine, Faes, Margaux, Harris, Kristina, Oortwijn, Alessandra, Daniele, Patrick, Patel, Haridarshan, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274306/ https://www.ncbi.nlm.nih.gov/pubmed/36756874 http://dx.doi.org/10.1093/ecco-jcc/jjad018

Ejemplares similares

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
por: Danese, Silvio, et al.
Publicado: (2023)

Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
por: Dotan, Iris, et al.
Publicado: (2023)

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
por: Loftus, Edward V, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study
por: Allocca, Mariangela, et al.
Publicado: (2018)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
por: Clemow, D B, et al.
Publicado: (2023)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
por: Vermeire, Séverine, et al.
Publicado: (2021)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
por: Parkes, Gareth, et al.
Publicado: (2023)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
por: Ungaro, Ryan, et al.
Publicado: (2019)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA
por: Travis, Simon, et al.
Publicado: (2017)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
por: Schreiber, Stefan, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

A snapshot of the ongoing clinical research on COVID-19
por: Piovani, Daniele, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n2d6artdb2de718atjob3ku9je